Small molecule MIF inhibitors for the treatment of inflammatory bowel disease

Project Abstract:

The innovators have identified potent small molecule MIF inhibitors that reduce inflammationassociated cytokines in blood cell and mouse assays and simultaneously exhibit favorable drug likeness properties including oral availability The molecules hold promise for the treatment of human inflammatory bowel diseases IBD including ulcerative colitis and Crohns disease The currently approved medications for IBD treatment a multibilliondollar market include antiinflammatories such as corticosteroids and immune system suppressors including injectable antiTNF antibodies such as Humira These medications suffer from side effects high cost and unreliable efficacy There is a pressing need for safe effective oral small molecules that operate by orthogonal mechanisms Our macrophage migration inhibitory factor MIF inhibitors MW 400 reduce inflammationassociated cytokines in blood cell and mouse assays They simultaneously exhibit promising drug likeness properties including oral availability permeability metabolic stability and colon localization and are stable low cost and nontoxic New MIF inhibitors may have additional potential applications in treating cytokine storm afflictions multiple sclerosis rheumatoid arthritis and cancer

Program:

REACH 2019

Disease Area:

Gastroenterology

Project Completion Status:

Completed

Center Hub:

ROI

Indication:

Inflammatory Bowel Disease

University/Institution:

Rutgers University

Technology:

Small molecule drug

Startup Name:

Contact:

Pragati Sharma [email protected]